Avid Bioservices, Inc.
Avid Bioservices, Inc. (Form: 8-K, Received: 01/18/2018 17:06:05)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 18, 2018


AVID BIOSERVICES, INC.  

(Exact name of registrant as specified in its charter)

 

Delaware   001-32839   95-3698422
(State of other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)
         
2642 Michelle Drive, Suite 200, Tustin, California 92780
(Address of Principal Executive Offices)
         
Registrant’s telephone number, including area code: (714) 508-6000
 
Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933( § 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( § 240.12b-2 of this chapter).

o             Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o  

 

 

 

     
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On January 18, 2018, Avid Bioservices, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 45,210,608 shares of the Company’s common stock outstanding (as of the record date of November 27, 2017) and entitled to vote, 37,204,966 shares were present in-person or represented by proxy, representing 82% of the total outstanding shares entitled to vote. The final voting results of each proposal voted on at the Annual Meeting are set forth below. For more information about the proposals set forth below, please refer to the Company’s definitive proxy statement filed with the Securities and Exchange Commission on December 7, 2017.

 

Proposal No. 1: Election of Directors

 

The Company’s stockholders elected each of the seven nominees named below to serve on the Company’s Board of Directors until the Company’s 2018 Annual Meeting of Stockholders. The votes were as follows:

 

Nominee

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

Mark R. Bamforth   18,291,530   750,270   18,163,166
Joseph Carleone, Ph.D.   18,279,401   762,399   18,163,166
Richard B. Hancock   18,322,847   718,953   18,163,166
Roger J. Lias, Ph.D.   18,249,302   792,498   18,163,166
Joel McComb   18,325,118   716,682   18,163,166
Gregory P. Sargen   18,319,520   722,280   18,163,166
Patrick D. Walsh   18,270,723   771,077   18,163,166

 

Proposal No. 2: Ratification of Independent Registered Public Accounting Firm

 

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2018. The votes were as follows:

 

Votes For   Votes Against   Abstain
36,433,192   640,525   131,249

  

Proposal No. 3: To Approve, On an Advisory Basis, the Compensation of the Named Executive Officers

 

The Company’s stockholders approved, on an advisory basis, a non-binding resolution approving the compensation of the named executive officers as disclosed in the Company’s definitive proxy statement for its 2017 Annual Meeting of Stockholders. The votes were as follows:

 

Votes For   Votes Against   Abstain   Broker Non-Votes
15,178,069   3,625,027   238,704   18,163,166

 

Proposal No. 4: To Determine, On an Advisory Basis, the Frequency of the Advisory Vote on the Compensation of the Named Executive Officers

 

The Company’s stockholders voted, on an advisory basis, that the frequency of named executive officer compensation advisory votes should be every year. The votes were as follows:

 

1 Year   2 Years   3 Years   Abstain   Broker Non-Votes
18,696,750   104,956   174,573   65,521   18,163,166

 

Based on these voting results, and consistent with the recommendation of the Company’s board of directors (the “Board”), the Board has determined that the Company will hold an advisory vote on named executive officer compensation every year until its next required frequency vote.

 


  2  
 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  AVID BIOSERVICES, INC.
   
Date: January 18, 2018 By:  /s/ Paul J. Lytle
    Paul J. Lytle
Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 


  3